Simplex Trading
LXEO icon

Simplex Trading’s Lexeo Therapeutics LXEO Stock Holding History

Simplex Trading’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86K Sell
400
-100
-20% -$541 ﹤0.01% 8660
2026
Q1 		$2.87K Buy
500
+200
+67% +$1.42K ﹤0.01% 8207
2025
Q4 		$2.98K Sell
300
-700
-70% -$6.39K ﹤0.01% 7689
2025
Q3 		$6K Sell
1,000
-1,000
-50% -$4.84K ﹤0.01% 8204
2025
Q2 		$8K Buy
+2,000
New +$6.58K ﹤0.01% 7475

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Simplex Trading's LXEO Position: Q2 2026 in Review

Simplex Trading sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 1,240 shares — an estimated $6.71K sold.

Simplex Trading first reported a position in LXEO in Q3 2025 and held it in 3 quarters. The position peaked at $129K in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Simplex Trading reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 1,240 Lexeo Therapeutics shares in Q2 2026, an estimated $6.71K.
  • Simplex Trading first reported a position in Lexeo Therapeutics in Q3 2025 and held it in 3 quarters.
  • Simplex Trading's Lexeo Therapeutics position peaked at $129K in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.